
    
      This is a Phase 1, randomized, first-in-human (FIH) study to assess the safety, tolerability,
      and pharmacokinetics (PK) of AZD4076 tetracosasodium following subcutaneous (SC)
      administration in healthy male subjects at increasing single doses
    
  